Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News VBI Vaccines Inc VBIVQ

Healthcare Biotechnology
VBI Vaccines Inc. is a commercial-stage biopharmaceutical company. Through its approach to virus-like particles (VLPs), including an enveloped VLP (eVLP) platform technology and a proprietary mRNA-launched eVLP (MLE) platform technology, the Company develops vaccine candidates that mimic the natural presentation of viruses, designed to elicit the innate power of the human immune system. The... see more

Recent & Breaking News (GREY:VBIVQ)

VBI Vaccines Announces Phase 3 Clinical Program for Sci-B-Vac(TM) Hepatitis B Vaccine

Marketwired July 11, 2017

VBI Vaccines Announces Results of Annual General and Special Meeting

MarketWire Canada June 28, 2017

VBI Vaccines Added to Russell 2000® and Russell 3000® Indexes

MarketWire Canada June 26, 2017

VBI Vaccines Reports Positive Outcome from Phase III Pre-IND Discussions with the FDA for Hepatitis B Vaccine, Sci-B-Vac(TM)

MarketWire Canada June 19, 2017

VBI Vaccines to Present at Jefferies 2017 Global Healthcare Conference

MarketWire Canada June 5, 2017

VBI Vaccines Provides Update on its Congenital CMV Phase I Clinical Study

MarketWire Canada May 2, 2017

VBI Vaccines to Present Updates on Multiple Programs at the World Vaccine Congress

MarketWire Canada April 5, 2017

The Market In 5 Minutes

Benzinga.com  April 4, 2017

Exclusive: VBI Vaccines CEO Talks Pipeline, Investor Backing, Hep. B Vaccine Opportunity

Benzinga.com  April 3, 2017

VBI Vaccines Appoints Avi Mazaltov as Global Head of Manufacturing and SciVac General Manager; Rehovot, Israel Site

MarketWire Canada March 30, 2017

Meet VBI Vaccines, The Biotech Up 100% In 2017

Benzinga.com  March 7, 2017

VBI Vaccines Receives Positive Response from Health Canada's Initial Evaluation of the Proposed Sci-B-Vac Phase III Clinical Program

MarketWire Canada February 22, 2017

VBI Vaccines Receives Positive EMA Scientific Advice Regarding Sci-B-Vac(TM) Phase III Clinical Study

MarketWire Canada February 7, 2017

VBI Vaccines Closes $23.6 Million Financing from Perceptive Advisors

MarketWire Canada December 6, 2016

VBI Vaccines Reports Rapid Seroprotection Results from an Interim Analysis of a Phase IV Postmarketing Study of its Sci-B-Vac(TM) Hepatitis B Vaccine

MarketWire Canada November 14, 2016

VBI Vaccines to Present at the Society of Neuro-Oncology Annual Meeting

MarketWire Canada November 10, 2016

VBI Vaccines to Present Zika Vaccine Program Poster at the Keystone Symposia on Translational Vaccinology for Global Health

MarketWire Canada October 27, 2016

VBI Vaccines Completes Pre-IND Meeting for its Glioblastoma Immunotherapy Candidate

MarketWire Canada October 11, 2016

VBI Vaccines to Present at the World Vaccine Congress Europe

MarketWire Canada October 5, 2016

VBI Vaccines Announces Results of Annual General and Special Meeting

MarketWire Canada September 26, 2016